We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2.
- Authors
Sehn, L. H; Chamuleau, M.; Lenz, G.; Clausen, M. R.; Haioun, C.; Izutsu, K.; Davies, A.; Zhu, J.; Oki, T.; Szafer‐Glusman, E.; Conlon, R.; Chiou, H.; Ipe, D.; Elliot, B.; Wu, J.; Salles, G.
- Abstract
Epcoritamab is a subcutaneously administered, bispecific antibody that binds CD3 on T cells and CD20 on B cells, inducing potent and selective T-cell-mediated killing of malignant CD20+ B cells (Hutchings et al., I Lancet i 2021). B Introduction: b In pts with newly diagnosed DLBCL, standard treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has a 5-year progression-free survival (PFS) rate of 67.0%, 58.4%, and 45.8% for International Prognostic Index (IPI) 2, 3, and 4-5, respectively (Ruppert et al., I Blood i 2020). PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R-CHOP VERSUS R-CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): EPCORE DLBCL-2.
- Subjects
DIFFUSE large B-cell lymphomas; CLINICAL trials; ANTINEOPLASTIC combined chemotherapy protocols
- Publication
Hematological Oncology, 2023, Vol 41, p849
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3166_OT28